Groningen, the Netherlands, April 15, 2014 — Biotechnology com­pa­ny Mucosis B.V. today announced that it entered into a long-term col­lab­o­ra­tion and license agree­ment with China-based Changchun BCHT Biotechnology Co (BCHT) and raised EUR 5 mil­lion, in a new financ­ing round.
Under the agree­ment with BCHT, Mucosis will receive an equi­ty invest­ment along with cus­tom­ary pay­ments includ­ing roy­al­ties in return for a license to its SynGEM® pre­fu­sion F vac­cine can­di­date for pre­ven­tion of RSV and the Mimopath® plat­form for oth­er dis­ease tar­gets with­in the People’s Republic of China on an exclu­sive basis and non-exclu­sive­ly in cer­tain oth­er Asian coun­tries. Further details of the agree­ment were not dis­closed.
Changchun BCHT Biotechnology Co. was estab­lished in 2004 and is a 600-per­son bio­phar­ma­ceu­ti­cal enter­prise engag­ing in research, devel­op­ment, pro­duc­tion and mar­ket­ing of vac­cines, bio­log­ics and pep­tide drugs. BCHT has a well-estab­lished inno­v­a­tive orga­ni­za­tion led by tal­ent­ed researchers and sup­port­ed by state-of-the-art facil­i­ties. The man­age­ment team con­sists of mem­bers with broad inter­na­tion­al back­ground along with exten­sive expe­ri­ence in China’s bio­phar­ma­ceu­ti­cal indus­try.
“We are pleased with BCHT join­ing a group of investors who share our con­fi­dence in the poten­tial of our Mimopath® tech­nol­o­gy and the pro­pri­etary SynGEM® pre­fu­sion F RSV vac­cine can­di­date. We believe that our Mimopath® plat­form com­bined with BCHT’s exper­tise in vac­cine devel­op­ment cre­ates a sub­stan­tial oppor­tu­ni­ty in China and oth­er parts of Asia to devel­op dif­fer­en­ti­at­ed and med­ical­ly rel­e­vant vac­cines”, said Thomas Johnston, CEO of Mucosis. “We see this part­ner­ship as a fur­ther val­i­da­tion of our clin­i­cal-stage plat­form and its poten­tial to com­bat infec­tious dis­eases. Lastly, we are grate­ful to Link China Pharma Solutions of Cambridge, UK for their invalu­able assis­tance in bro­ker­ing this deal.”
“We are delight­ed to form this strate­gic part­ner­ship with Mucosis BV to advance the RSV SynGEM® vac­cine pro­gram and devel­op oth­er vac­cine can­di­dates based on the val­i­dat­ed Mimopath® plat­form tech­nol­o­gy. I believe this busi­ness rela­tion­ship between our two com­pa­nies will strength­en our pipeline of new vac­cine prod­ucts.” said Dr Kong, President of Changchun BCHT Biotechnology Co.
In addi­tion to BCHT, the financ­ing round was sup­port­ed by Mucosis’s cur­rent investors, which include BioGeneration Ventures, MedSciences Capital, NV NOM (Investment and Development Agency for the Northern Netherlands), and Utrecht Holdings.
For fur­ther infor­ma­tion please con­tact:
Thomas Johnston CEO Mucosis +31 (50) 8200050

Leave a Reply

Your email address will not be published. Required fields are marked *